中国普外基础与临床杂志

中国普外基础与临床杂志

胆囊癌的诊断与治疗进展

查看全文

目的阐述当前胆囊癌诊断和治疗方面的最新研究进展。方法复习近年国内外胆囊癌诊治方面的有关文献,就胆囊癌的诊断、分期方法和治疗进展进行系统综述。结果诊断胆囊癌的方法众多,主要为影像学方法,与胆囊癌相关的肿瘤标志物和基因也能提供一定的帮助。外科手术切除仍是可能治愈胆囊癌的唯一方法,但手术切除范围和时机仍存在争议;放化疗和基因治疗也在胆囊癌的治疗中占有重要地位。结论胆囊癌的诊断仍以影像学检查为首选,肿瘤标志物和基因诊断具有广阔的前景。胆囊癌应采取以手术治疗为主的综合治疗方式,基因干预和精确靶向治疗是未来的发展方向。

ObjectiveTo review the latest advances in diagnosis and treatment of gallbladder carcinoma.MethodsThe recent literatures on diagnosis and treatment of gallbladder carcinoma at home and abroad were reviewed, and the diagnosis, staging and treatment progress of gallbladder carcinoma were systematically reviewed.ResultsThere are many methods to diagnose gallbladder carcinoma, among which imaging methods are commonly used, as well as various tumor markers and gallbladder carcinoma-related genes. Surgical resection is still the only possible cure for gallbladder carcinoma, but the scope and timing of surgical resection are still controversial. Radiotherapy, chemotherapy and gene therapy also play an important role in the treatment of gallbladder carcinoma.ConclusionsImaging examination is still the first choice for the diagnosis of gallbladder carcinoma. The tumor markers and gene diagnosis has broad prospects. Gallbladder carcinoma is mainly treated by surgery. Gene intervention and precise targeted therapy are the future development direction.

关键词: 胆囊癌; 诊断进展; 病理分期; 治疗方法

Key words: gallbladder carcinoma; progress in diagnosis; pathological stage; therapies

引用本文: 于志远, 孙岩. 胆囊癌的诊断与治疗进展. 中国普外基础与临床杂志, 2019, 26(3): 282-287. doi: 10.7507/1007-9424.201812102 复制

登录后 ,请手动点击刷新查看全文内容。 没有账号,
登录后 ,请手动点击刷新查看图表内容。 没有账号,
1. 吴森焱, 蔡军. 胆囊癌诊疗现状. 实用临床医学, 2016, 17(2): 102-107.
2. Inui K, Yoshino J, Miyoshi H. Diagnosis of gallbladder tumors. Intern Med, 2011, 50(11): 1133-1136.
3. Zhang HP, Bai M, Gu JY, et al. Value of contrast-enhanced ultrasound in the differential diagnosis of gallbladder lesion. World J Gastroenterol, 2018, 24(6): 744-751.
4. Miwa H, Numata K, Sugimori K, et al. Differential diagnosis of gallbladder polypoid lesions using contrast-enhanced ultrasound. Abdom Radiol(NY), 2018 Nov 26.[Epub ahead of print].
5. Ogura T, Kurisu Y, Masuda D, et al. Can endoscopic ultrasound-guided fine needle aspiration offer clinical benefit for thick-walled gallbladders? Dig Dis Sci, 2014, 59(8): 1917-1924.
6. 曾茂迪, 曾燕. 胆囊癌影像诊断研究进展. 现代医药卫生, 2018, 34(14): 2195-2198.
7. 林国福, 程莎莎, 梁健. CT和MRI对中晚期胆囊癌周围脏器侵袭和转移的诊断价值. 中国普外基础与临床杂志, 2012, 5(19): 562-564.
8. 陈藤, 吴宇. 超声、MRI、CT在诊断原发性胆囊癌患者中应用. 中国CT和MRI杂志, 2015, 13(11): 66-69.
9. 刘雪松, 李凤华. 胆囊癌影像学研究进展. 临床超声医学杂志, 2014, 16(12): 830-833.
10. 吴平, 周克, 陈治明, 等. 18F氟代脱氧葡萄糖正电子发射断层成像术/计算机断层扫描显像在胆囊癌中的诊断价值. 实用医技杂志, 2014, 21(2): 131-135.
11. 汪娇, 徐文贵, 戴东, 等. 18F-FDG PET/CT显像在原发性胆囊癌诊断中的价值及优势. 中国肿瘤临床, 2013, 40(2): 103-106.
12. Ke QH, He ZL, Duan X, et al. Chronic cholecystitis with hilar bile duct stricture mimicking gallbladder carcinoma on positron emission tomography: A case report. Mol Clin Oncol, 2013, 1(3): 517-520.
13. Kumar R, Sharma P, Kumari A, et al. Role of 18F-FDG PET/CT in detecting recurrent gallbladder carcinoma. Clin Nucl Med, 2012, 37(5): 431-435.
14. Puranik AD, Purandare N, Aqrawal A, et al. Bone marrow metastases in an otherwise operable gall bladder cancer: rare site of distant metastases detected on FDG PET/CT. Clin Nucl Med, 2014, 39(2): e169-e172.
15. Sahoo MK, Sharma P, Suman S, et al. Gallbladder carcinoma metastasizing to adrenal gland: a rare site demonstrated with (18)F-FDG PET/CT. Clin Nucl Med, 2014, 39(2): 184-185.
16. 邱翔, 杨科, 赵玉婷, 等. PET/MRI在肿瘤研究中的新进展. 国际医学放射学杂志, 2017, 40(1): 64-67.
17. Liu F, Wang JK, Ma WJ, et al. Clinical value of preoperative CA19-9 levels in ebaluating resectability of gallbladder carcinoma. ANZ J Surg, 2018 Oct 10.[Epub ahead of print].
18. 龚平明, 姚成礼, 赵鑫. 血清CA199、CA125、CEA、CA153联合检测对胆囊癌的诊断价值. 山东医药, 2013, 53(23): 58-59.
19. 刘星雨, 范正军. 高尔基体蛋白GP73和Ki-67在胆囊癌中的表达及临床意义. 实用医学杂志, 2017, 33(1): 47-50.
20. Halder S, Kundu S, Chakraborty J, et al. Significance of HER2 and Ki-67 in preneoplastic lesions and carcinoma of gallbladder. J Gastrointest Cancer, 2018 Aug 29.[Epub ahead of print].
21. 张华洋. 胆囊癌生物学标志物研究进展. 中国普通外科杂志, 2014, 23(8): 1112-1116.
22. Hsu M, Sasaki M, Igarashi S, et al. KRAS and GNAS mutations and p53 overexpression in biliary intraepithelial neoplasia and intrahepatic cholangiocarcinomas. Cancer, 2013, 119(9): 1669-1674.
23. 陈义钢, 顾琛. 转移抑制基因1和微血管密度在胆囊癌中的表达及其临床意义. 中国现代医学杂志, 2017, 27(7): 46-49.
24. 孔炜伟, 陈骏, 何建, 等. 美国癌症联合委员会胆囊癌分期系统(第8版)更新的多学科解读. 中国普外基础与临床杂志, 2017, 9(24): 1053-1056.
25. 汤朝晖, 田孝东, 魏妙艳, 等. 美国癌症联合委员会胆道恶性肿瘤分期系统(第8版)更新解读. 中国实用外科杂志, 2017, 37(24): 248-254.
26. Lee AJ, Chiang YJ, Lee JE, et al. Validation of American Joint Committee on Cancer eighth staging system for gallbladder cancer and its lymphadenectomy guidelines. Journal of Surgical Research, 2018, 230: 148-154.
27. 侯启慧. 根治性切除术与腹腔镜胆囊切除术治疗早期胆囊癌患者的临床效果对比. 中国民康医学, 2017, 29(1): 31-32.
28. 谌利, 贾乾斌. 根治性胆囊切除术与腹腔镜胆囊切除术治疗早期胆囊癌患者的疗效. 医疗设备, 2018, 31(9): 11-9120.
29. 陈亚进, 徐鋆耀. 腹腔镜技术在胆囊癌根治术中的应用评价. 中国实用外科杂志, 2016, 36(10): 1040-1044.
30. 陈柏羽. 腹腔镜胆囊切除术与根治性切除术治疗胆囊癌的临床效果观察. 临床合理用药杂志, 2016, 9(29): 98-99.
31. 别平, 陈志宇. 胆囊癌诊治的困惑及未来突破方向. 中国实用外科杂志, 2016, 36(10): 1021-1024.
32. 张铃福, 候纯升, 郭丽梅. 术中冰冻或术后石蜡病理报告T1b期胆囊癌的外科治疗策略. 北京大学学报(医学版), 2017, 49(06): 1034-1037.
33. You DD, Lee HG, Paik KY, et al. What is an adequate extent of resection for T1 gallbladder cancers? Ann Surg, 2008, 247(5): 835-838.
34. Benson AB 3rd, Abrams TA, Ben-Josef E, et al. NCCN clinical practice guidelines in oncology: hepatobiliary cancers. J Natl Compr Canc Netw, 2009, 7(4): 350-391.
35. 王刚, 张龙辉, 张长坤, 朱继业, 冷希圣, 王东. 不同手术方式治疗早期胆囊癌的临床疗效比较. 中国普外基础与临床杂志, 2017, 24(10): 1220-1225.
36. Dasari BVM, Ionescu MI, Pawlik TM, et al. Outcomes of surgical resection of gallbladder cancer in patients presenting with jaundice: A systematic review and meta-analysis. J Surg Oncol, 2018, 118(3): 477-485.
37. Tatli F, Ozgönül A, Yucel Y, et al. Incidental gallbladder cancer at cholecystectomy. Ann Ital Chir, 2017, 6: 399-402.
38. Dincel O, Goksu M, Hatipoglu HS. Importance of routine histopathological examination of a gallbladder surgical specimen:Unexpected gallbladder cancer. J Cancer Res Ther, 2018, 14(6): 1325-1329.
39. 李春生, 邹奇, 王勇. 腹腔镜胆囊切除术意外胆囊癌21例临床诊治及预后分析. 肝胆胰外科杂志, 2015, 27(3): 241-243.
40. 张艳林, 张杰峰. 32例腹腔镜胆囊切除术意外胆囊癌的临床诊治. 现代生物医学进展, 2014, 14(7): 1320-1322, 1307.
41. 张亦驰, 王许安, 刘颖斌. 放射治疗在胆囊癌综合治疗中的应用进展. 肝胆胰外科杂志, 2017, 29(5): 430-432, 436.
42. 水永杰, 魏启春. 辅助放化疗在胆囊综合治疗中的作用和地位. 中国实用外科杂志, 2016, 36(10): 1122-1124.
43. Hakeem AR, Papoulas M, Menon KV. The role of neoadjuvant chemotherapy or chemoradiotherapy for advanced gallbladder cancer-A systematic review. Eur J Surg Oncol, 2019, 45(2): 83-91.
44. Dierks J, Gaspersz MP, Belkouz A, et al. Translating the ABC-02 trial daily practice:outcome of palliative treatment in patients with unresectable biliary tract cancer treated with gemcitabine and cisplatin. Acta Oncol, 2018, 57(6): 807-812.
45. Wang N, Xiang X, Chen K, et al. Targeting of NT5E by miR-30b and miR-340 attenuates proliferation, invasion and migration of gallbladder carcinoma. Biochimie, 2018, 146: 56-67.
46. Xue C, He Y, Hu Q, et al. Downregulation of P1M1 regulates glycolysis and suppresses tumor progression in gallbladder cancer. Cancer Manag Res, 2018, 10: 5101-5112.
47. 中国抗癌协会. 胆囊癌规范化诊治专家共识(2016). 临床肝胆病杂志, 2017, 33(4): 611-620.
48. Aloia TA, Javle M, Maithel SK, et al. Gallbladder cancer: expert consensus statement. HPB (Oxford), 2015, 17(8): 681-690.
49. Rajveer Hundal, Eldon A Shaffer. Gallbladder cancer: epidemiology and outcome. Clin Epidemiol, 2014, 6: 99-109.
50. 耿金宏, 袁金凤, 吴鸣, 等. 胆囊癌流行分布及高危因素探讨研究. 临床和实验医学杂志, 2012, 11(16): 1336-1337.